ACC.26丨聚焦血脂異常領(lǐng)域，盤點(diǎn)即將公布的最新研究進(jìn)展！

血脂異常作為心血管疾病的重要危險(xiǎn)因素，與動(dòng)脈粥樣硬化、冠心病、腦卒中等多種嚴(yán)重疾病的發(fā)生發(fā)展緊密相關(guān)，嚴(yán)重威脅著人們的健康。近年來，血脂領(lǐng)域的研究不斷取得新突破，從新型降脂藥物的研發(fā)到血脂管理策略的優(yōu)化，每一項(xiàng)進(jìn)展都備受關(guān)注。北京時(shí)間3月28日至30日，備受矚目的ACC.26學(xué)術(shù)會(huì)議將在美國(guó)新奧爾良盛大召開。作為心血管領(lǐng)域的國(guó)際盛會(huì)，本次大會(huì)眾多國(guó)際研究者發(fā)布了針對(duì)血脂異常的最新研究成果，POCKETIN特別匯集整理了相關(guān)日程，一起來先睹為快！

03月28日

1006. New Frontiers in Lipid Management
北京時(shí)間：22:42
EFFICACY AND SAFETY OF OLEZARSEN FOR THE MANAGEMENT OF DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLEDTRIALS
Olezarsen治療血脂異常的療效與安全性：隨機(jī)對(duì)照試驗(yàn)的系統(tǒng)評(píng)價(jià)與薈萃分析

S. Neppala

北京時(shí)間：23:18
LIPOPROTEIN(A)-TARGETED THERAPIES VERSUS PLACEBO/STANDARD CARE IN ASCVD: EFFECTS ON MACE, LP(A) REDUCTION AND SAFETY — SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS
脂蛋白(a)靶向治療對(duì)比安慰劑/標(biāo)準(zhǔn)治療在動(dòng)脈粥樣硬化性心血管疾病中的應(yīng)用：對(duì)主要不良心血管事件、脂蛋白(a)降低及安全性的影響——隨機(jī)對(duì)照試驗(yàn)的系統(tǒng)評(píng)價(jià)與薈萃分析

N. Lanka

1302. Cardiovascular Disease Prevention 01
北京時(shí)間：22:30
REAL-WORLD UTILIZATION AND PERSISTENCE OF LIPID-LOWERING THERAPIES AFTER PERCUTANEOUS CORONARY INTERVENTION (PCI)
經(jīng)皮冠狀動(dòng)脈介入治療后降脂治療的真實(shí)世界使用情況與持續(xù)性

Muhammad Raffey Shabbir

北京時(shí)間：22:30
IMPACT OF LOMITAPIDE ON LIPID PROFILES IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH): A SYSTEMATIC REVIEW AND SINGLE-ARM META-ANALYSIS
洛美他派對(duì)純合子家族性高膽固醇血癥血脂譜的影響：一項(xiàng)系統(tǒng)評(píng)價(jià)與單組薈萃分析

A. Akoum

北京時(shí)間：22:30
EFFICACY AND SAFETY OF RECATICIMAB FOR LDL-C AND LIPOPROTEIN(A) REDUCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS
瑞卡西單抗降低低密度脂蛋白膽固醇和脂蛋白(a)的療效與安全性：一項(xiàng)系統(tǒng)評(píng)價(jià)與薈萃分析

S. Fausto Girón

北京時(shí)間：22:30
SGLT2 INHIBITORS, BUT NOT DPP4 INHIBITORS,LOWER LDL-C ANDIMPROVE OUTCOMES IN PATIENTSWITH DIABETES AND CORONARY ARTERY DISEASE
SGLT2抑制劑，而非DPP4抑制劑，可降低糖尿病合并冠狀動(dòng)脈疾病患者的低密度脂蛋白膽固醇并改善結(jié)局

A. Theertham

1305. Congenital Heart Disease 01
北京時(shí)間：22:30
EXPLORING THE RELATIONSHIP BETWEEN ATRIAL REFRACTORINESS, DYSLIPIDEMIA AND ATRIAL FIBRILLATION IN CHILDREN AND YOUNG PERSONS
探討兒童與青少年心房不應(yīng)期、血脂異常及心房顫動(dòng)之間的關(guān)系

S. P. Behere

1310. Vascular Diseases 01
北京時(shí)間：22:30
DOSE-RESPONSE RELATIONSHIP AND EFFICACY OF EVINACUMAB FOR REFRACTORY AND GENETIC DYSLIPIDEMIAS A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
依維蘇單抗在難治性及遺傳性血脂異常中的劑量-反應(yīng)關(guān)系及療效：隨機(jī)對(duì)照試驗(yàn)的系統(tǒng)評(píng)價(jià)與薈萃分析

Syed Habib

1323. Heart Failure and Cardiomyopathies 01
北京時(shí)間：22:30
GLP-1 RECEPTOR AGONISTS IN HEART FAILURE WITH REDUCED/MILDLY REDUCED EF: 5-YEAR OUTCOMES AND EFFECT MODIFICATION BY OBESITY AND ETHNICITY
GLP-1受體激動(dòng)劑在射血分?jǐn)?shù)降低/輕度降低的心力衰竭中的應(yīng)用：5年結(jié)局及肥胖與種族的效應(yīng)修飾作用

H. Agarwal

03月29日

1019. Cellular Biology of Atherosclerotic Plaque
北京時(shí)間：00:36
OXIDIZED LDL TRIGGERS PYROPTOSIS IN VASCULAR SMOOTH MUSCLE CELLS AND SALIDROSIDE TREATMENT MITIGATES THIS PATHWAY TO IMPROVE PLAQUE STABILITY
氧化低密度脂蛋白觸發(fā)血管平滑肌細(xì)胞發(fā)生細(xì)胞焦亡，而紅景天苷治療可減輕該通路以改善斑塊穩(wěn)定性

許恒偉 陜西省人民醫(yī)院

北京時(shí)間：00:48
IMPAIRED EFFEROCYTOSIS IN RESPONSE TO LOW-DENSITY LIPID AND LOW SHEAR STRESS IN AN IN-VITROMODEL OF ATHEROSCLEROSIS
在動(dòng)脈粥樣硬化體外模型中，對(duì)低密度脂蛋白和低剪切應(yīng)力應(yīng)答的胞葬作用受損

Ruben Tapia-Orihuela

1324. CV Team 02
北京時(shí)間：00:00
FLORIDA CARDIOVASCULAR QUALITY NETWORK; THE CENTRAL ROLE OF ADVANCED PRACTICE PROFESSIONALS TO ACHIEVE A SUSTAINED TWO YEAR IMPROVEMENT IN CARDIOVASCULAR RISK IN HIGH RISK HYPERLIPIDEMIA PATIENTS
佛羅里達(dá)心血管質(zhì)量網(wǎng)絡(luò)：高級(jí)執(zhí)業(yè)醫(yī)師在高風(fēng)險(xiǎn)高脂血癥患者中實(shí)現(xiàn)心血管風(fēng)險(xiǎn)持續(xù)兩年改善的核心作用

Kim Seals

1325. Featured Fields 02
北京時(shí)間：00:00
CHRONOLOGICAL AGING AND PROGRESSION OF CORONARY ARTERY DISEASE: INSIGHTS FROM POOLED IVUS TRIALS OF LIPID-LOWERING THERAPIES
時(shí)序性衰老與冠狀動(dòng)脈疾病進(jìn)展：來自降脂治療匯總血管內(nèi)超聲試驗(yàn)的見解

A. Damluji

1326. Cardiovascular Disease Prevention 02
北京時(shí)間：00:00
THE RELATIONSHIP BETWEEN CYTOKINES AND LIPIDS WITH MRI-DERIVED MEASURES OF CARDIAC MORPHOLOGY IN MEXICAN AMERICANS
墨西哥裔美國(guó)人中細(xì)胞因子和血脂與磁共振成像衍生的心臟形態(tài)測(cè)量指標(biāo)之間的關(guān)系

V. O’Brien

北京時(shí)間：00:00
EFFECT OF AN EMR-EMBEDDED IN-HOSPITAL CLINICAL PATHWAY ON LIPID MANAGEMENT AFTER ACUTE CORONARY SYNDROME
嵌入電子病歷的院內(nèi)臨床路徑對(duì)急性冠狀動(dòng)脈綜合征后血脂管理的影響

Tatsuhiro Kataoka

北京時(shí)間：00:00
A SINGLE-CENTER RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN LIPOPROTEIN(A) AND LIPID LEVELS IN A PEDIATRIC POPULATION
脂蛋白(a)與兒童人群血脂水平關(guān)聯(lián)的單中心回顧性研究

Dorota Gruber

1328. Ischemic Heart Diseases 02
北京時(shí)間：00:00
RACIAL/ETHNIC AND SEX DISPARITIES IN LDL-C TESTING FREQUENCY POST CORONARY ARTERY BYPASS GRAFTING (CABG): INSIGHTS FROM A LARGE INTEGRATED, DIVERSE HEALTHCARE SYSTEM
冠狀動(dòng)脈旁路移植術(shù)后低密度脂蛋白膽固醇檢測(cè)頻率的種族/民族和性別差異：來自一個(gè)大型綜合性多元化醫(yī)療系統(tǒng)的見解

Janine Yang

1332. Coronary, Peripheral and Structural Interventions 02
北京時(shí)間：00:00
REFERENCE ZONE LIPID PLAQUE AND TIME TO RESTENOSIS PREDICT NEOATHEROSCLEROSIS ON OCT
參照區(qū)脂質(zhì)斑塊和再狹窄時(shí)間預(yù)測(cè)光學(xué)相干斷層掃描上的新發(fā)動(dòng)脈粥樣硬化

Nicholas Olivieri

1337. Complex Clinical Cases: Cardiovascular Disease Prevention 02
北京時(shí)間：00:00
LACK OF RESPONSE TO INCLISIRAN IN HIGH-RISK PATIENTS WITH ADVERSE EFFECTS TO TRADITIONAL LIPID-LOWERING THERAPIES
高危患者對(duì)英克司蘭無反應(yīng)并對(duì)傳統(tǒng)降脂治療產(chǎn)生不良反應(yīng)

Patricia Machado

1034. Cardiac Imaging Research: From Data to Decision
北京時(shí)間：01:42
PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID LOWERING THERAPY USING AI BASED OPTICAL FLOW RATIO: INSIGHTS FROM YELLOW III STUDY
使用基于人工智能的光學(xué)血流比評(píng)估最大降脂治療前后非阻塞性冠狀動(dòng)脈病變的生理變化：來自YELLOW III研究的見解

P. Chenniganahosahalli

1038. Drug Therapy in Valvular Heart Disease: Evaluating Evidence for Disease Modification and Outcome Improvement
北京時(shí)間：01:30
ASPIRIN THERAPY IN INDIVIDUALS WITH ELEVATED OXIDIZED PHOSPHOLIPIDS AND RISK OF CALCIFIC AORTIC VALVE DISEASE: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
阿司匹林治療在氧化磷脂升高個(gè)體中的應(yīng)用與鈣化性主動(dòng)脈瓣疾病風(fēng)險(xiǎn)：多民族動(dòng)脈粥樣硬化研究

A. C. Razavi

1348. CV Team 03
北京時(shí)間：01:30
FROM GRAFT TO GRAPH: REAL WORLD PRACTICES IN LIPID LOWERING AMONG TRANSPLANT PATIENTS
從移植到圖譜：移植患者中降脂治療的真實(shí)世界實(shí)踐

S. F. Weintraub

228. Bold Moves into the Future: The 2026 ACC/AHA Multisociety Guideline For Management of Dyslipidemia
北京時(shí)間：02:41
A New Era in Risk Assessment: The PREVENT Calculator in Dyslipidemia Management
風(fēng)險(xiǎn)評(píng)估的新紀(jì)元：PREVENT計(jì)算器在血脂異常管理中的應(yīng)用

Donald M. Lloyd-Jones

北京時(shí)間：03:03
The Risk Continuum: Lipid Management From Start to Finish
風(fēng)險(xiǎn)連續(xù)體：從頭到尾的脂質(zhì)管理

Pamela Bowe Morris

1052. Targeting Lp(a) to Reduce Risk
北京時(shí)間：03:00
LP(A)-CORRECTED APOB-P/HDL-P RATIO STRONGLY PREDICTS ASCVD EVENTS: UK BIOBANK INSIGHTS
LP(A)-校正的APOB-P/HDL-P比值可強(qiáng)效預(yù)測(cè)動(dòng)脈粥樣硬化性心血管疾病事件：來自英國(guó)生物樣本庫(kù)的見解

E. S. Epstein

北京時(shí)間：03:12
LIPOPROTEIN(A), OXIDIZED PHOSPHOLIPIDS AND TENSILE CLOT STRENGTH MEASURED BY THROMBOELASTOGRAPHY IN PATIENTS UNDERGOING PERCUTANEOUS INTERVENTION
接受經(jīng)皮介入治療患者的脂蛋白(a)、氧化磷脂與血栓彈力圖測(cè)定的血栓拉伸強(qiáng)度

Paul Gurbel

1060. ACC Complex Clinical Cases: Cardiovascular Disease Prevention
北京時(shí)間：03:48
ACUTE-ONSET CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PRECIPITATED BY PCSK9 INHIBITOR DOSE ESCALATION: A COMPLEX CASE IN DYSLIPIDEMIA MANAGEMENT
由PCSK9抑制劑劑量遞增引發(fā)的急性發(fā)作性慢性炎性脫髓鞘性多發(fā)性神經(jīng)病：一例復(fù)雜的血脂異常管理案例

C. Stephenson-Moe

1374. Cardiovascular Disease Prevention 04
北京時(shí)間：03:00
LIPID SUBFRACTIONS AND SUBCLINICAL ATHEROSCLEROSIS PROGRESSION: A LIPIDOMICS APPROACH TO CARDIOVASCULAR RISK IN THE BRAZILIAN LONGITUDINAL STUDY OF ADULT HEALTH ELSA BRAZIL
脂質(zhì)亞組分與亞臨床動(dòng)脈粥樣硬化進(jìn)展：巴西成人健康縱向研究中脂質(zhì)組學(xué)方法對(duì)心血管風(fēng)險(xiǎn)的研究

L. F. Carvalho

北京時(shí)間：03:00
WOMEN ARE LESS LIKELY THAN MEN TO RECEIVE ADD-ON NONSTATIN LIPID-LOWERING THERAPY (LLT) AND TO ADHERE TO LLT: A SYSTEMATIC REVIEW
女性接受附加非他汀類降脂治療及堅(jiān)持該治療的可能性低于男性：一項(xiàng)系統(tǒng)評(píng)價(jià)

Alejandro Victores

1376. Ischemic Heart Diseases 04
北京時(shí)間：03:00
LIPID PROFILES UNDERLIE PROTECTION FROM ATHEROSCLEROSIS SEEN IN PATIENTS WITH ASCENDING THORACIC AORTIC ANEURYSMS
血脂譜是升主動(dòng)脈瘤患者對(duì)動(dòng)脈粥樣硬化具有保護(hù)作用的基礎(chǔ)

Asanish Kalyanasundaram

北京時(shí)間：03:00
PATTERNS AND CHARACTERISTICS OF ASCVD EVENTS IN PATIENTS ≥65 YEARS WITH LP(A) ≥50 MG/DL: PREMATURE, AVERAGE, AND NO EVENTS
65歲及以上脂蛋白(a) ≥50 mg/dL患者動(dòng)脈粥樣硬化性心血管疾病事件的模式與特征：早發(fā)、平均發(fā)生與無事件

V. T. Le

1380. Coronary, Peripheral and Structural Interventions 04
北京時(shí)間：03:00
EFFECT OF LIPID-LOWERING THERAPY ON INTRACORONARY IMAGING ENDPOINTS FOLLOWING PACLITAXEL-COATED BALLOON TREATMENT
降脂治療對(duì)紫杉醇涂層球囊治療后冠狀動(dòng)脈內(nèi)影像學(xué)終點(diǎn)的影響

Tamara Dijkstra

1385. Complex Clinical Cases: Cardiovascular Disease Prevention 04
北京時(shí)間：03:00
ROBUST LP(A) REDUCTION WITH COMBINED TOCILIZUMAB AND INCLISIRAN IN A HIGH-RISK INFLAMMATORY PATIENT
聯(lián)合托珠單抗與英克司蘭在高風(fēng)險(xiǎn)炎癥患者中實(shí)現(xiàn)脂蛋白(a)的顯著降低

Robert Luceri

1069. Next-Generation Lipid Treatement Options
北京時(shí)間：04:54
EFFECTIVENESS OF LDL-C LOWERING WITH ALIROCUMAB AND INCLISIRAN IN A CLINICAL PRACTICE SETTING
阿利西尤單抗和英克司蘭在臨床實(shí)踐環(huán)境中降低低密度脂蛋白膽固醇的有效性

M. Banach

1397. Featured Fields 05
北京時(shí)間：04:30
LIPID PROFILES AND FAST FOOD CONSUMPTION PATTERNS AMONG YOUNG AND OLDER U.S. ADULTS: AN NHANES 2008-2018 ANALYSIS
美國(guó)年輕與年長(zhǎng)成人的血脂譜和快餐消費(fèi)模式：2008-2018年美國(guó)國(guó)家健康與營(yíng)養(yǎng)調(diào)查分析

H. Shah

1398. Cardiovascular Disease Prevention 05
北京時(shí)間：04:30
FLORIDA CARDIOVASCULAR QUALITY NETWORK: TWO YEAR RESULTS CONFIRM A SUSTAINED IMPROVEMENT IN CARDIOVASCULAR RISK IN HIGH RISK HYPERLIPIDEMIA PATIENTS
佛羅里達(dá)心血管質(zhì)量網(wǎng)絡(luò)：兩年結(jié)果證實(shí)高風(fēng)險(xiǎn)高脂血癥患者心血管風(fēng)險(xiǎn)的持續(xù)改善

A. Allen Seals

北京時(shí)間：04:30
THE IMPACT OF STATIN THERAPY ON LIPID PROFILES AND ATHEROSCLEROTIC MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS: A META-ANALYSIS
他汀類藥物治療對(duì)系統(tǒng)性紅斑狼瘡患者血脂譜和動(dòng)脈粥樣硬化標(biāo)志物的影響：一項(xiàng)薈萃分析

Danielle Howell

北京時(shí)間：04:30
LIPOPROTEIN(A) AND OXIDIZED PHOSPHOLIPIDS-APOLIPOPROTEIN B, BIOMARKERS OF RISK IN CARDIAC TRANSPLANT OUTCOMES
脂蛋白(a)和氧化磷脂-載脂蛋白B：心臟移植結(jié)局的風(fēng)險(xiǎn)生物標(biāo)志物

Andrew Kao

1419. Heart Failure and Cardiomyopathies 05
北京時(shí)間：04:30
HYPERLIPIDEMIA AS A PREDICTOR OF EPICARDIAL ADIPOSITY IN PATIENTS WITH HEART FAILURE WITH PRESERVED BUT NOT REDUCED EJECTION FRACTION
高脂血癥作為射血分?jǐn)?shù)保留而非降低的心力衰竭患者心外膜脂肪量的預(yù)測(cè)因子

M. C. Volk

233. New Kids on the Block in the Battle Against PAD
北京時(shí)間：05:15
Novel Lipid Therapies in PAD
外周動(dòng)脈疾病中的新型脂質(zhì)療法

Naomi M. Hamburg

1084. Evolving Non-Statin Lipid Therapies
北京時(shí)間：22:54
LIPID-LOWERING EFFICACY AND SAFETY OF RECATICIMAB IN DYSLIPIDEMIA PATIENTS WITH OR WITHOUT TYPE 2 DIABETES MELLITUS: A POOLED PATIENT-LEVEL SUBGROUP ANALYSIS
瑞卡西單抗在伴或不伴2型糖尿病的血脂異常患者中的降脂療效與安全性：一項(xiàng)患者水平匯總的亞組分析

孫燕依 上海交通大學(xué)醫(yī)學(xué)院附屬瑞金醫(yī)院

北京時(shí)間：23:06
EFFICACY AND SAFETY OF OBICETRABIP IN REDUCING ATHEROGENIC LIPIDS: A SYSTEMATIC REVIEW AND DOSE RESPONSE META-ANALYSIS WITH TRIAL SEQUENTIAL ANALYSIS
Obicetrapib降低致動(dòng)脈粥樣硬化脂質(zhì)的療效與安全性：一項(xiàng)系統(tǒng)評(píng)價(jià)、劑量反應(yīng)薈萃分析及試驗(yàn)序貫分析

Prutha Pathak

1422. Cardiovascular Disease Prevention 06
北京時(shí)間：22:30
EFFECT OF BASELINE LIPID LEVELS OR STATIN USE ON FINERENONE TREATMENT OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY POST HOC ANALYSIS
基線血脂水平或他汀類藥物使用對(duì)慢性腎臟病合并2型糖尿病患者非奈利酮治療結(jié)局的影響：FIDELITY事后分析

A. Verma

1433. Complex Clinical Cases: Cardiovascular Disease Prevention 06
北京時(shí)間：22:30
AGGRESSIVE LIPID LOWERING IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: 29 YEARS EVENT-FREE SURVIVAL AFTER PREMATURE STEMI
雜合子家族性高膽固醇血癥的強(qiáng)化降脂治療：早發(fā)ST段抬高型心肌梗死后29年無事件生存

Robert Luceri, MD

北京時(shí)間：22:30
SITOSTEROLEMIA: A RARE, UNDERDIAGNOSED GENETIC DYSLIPIDEMIA
谷固醇血癥：一種罕見、未被充分診斷的遺傳性血脂異常

Boran Mao

267. From Pharm to Table: An Update on Cardiac Prevention Medications
北京時(shí)間：23:55
Tasting Menu of the Newest Lipid Medications
最新降脂藥物的品鑒菜單

Ashley Arana Waring

4505. Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
北京時(shí)間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動(dòng)：降低動(dòng)脈粥樣硬化性心血管疾病風(fēng)險(xiǎn)的新節(jié)奏

Tyler J. Gluckman

北京時(shí)間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動(dòng)：降低動(dòng)脈粥樣硬化性心血管疾病風(fēng)險(xiǎn)的新節(jié)奏

Viet T. Le

北京時(shí)間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動(dòng)：降低動(dòng)脈粥樣硬化性心血管疾病風(fēng)險(xiǎn)的新節(jié)奏

Erin D. Michos

北京時(shí)間：07:30
Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
隨血脂管理律動(dòng)：降低動(dòng)脈粥樣硬化性心血管疾病風(fēng)險(xiǎn)的新節(jié)奏

Pam Taub

3001. Putting the Guidelines into Practice: Building a State-of-the-Art Lipid and Cardiometabolic Clinic
北京時(shí)間：07:10
Key Implementation Highlights from the 2026 Guideline on the Management of Dyslipidemia
2026年血脂異常管理指南的關(guān)鍵實(shí)施要點(diǎn)

Pamela Bowe Morris

北京時(shí)間：07:25
Nuts and Bolts of a Lipid and Cardio-Kidney-Metabolic Clinic
血脂與心臟-腎臟-代謝門診的基本要素

Anum Saeed

1350. Cardiovascular Disease Prevention 03
北京時(shí)間：01:30
RETHINKING RISK THRESHOLDS: LP(A) STRATIFICATION REVEALS STEPWISE RISE IN MORTALITY AND MACE
重新思考風(fēng)險(xiǎn)閾值：脂蛋白(a)分層顯示死亡率和主要不良心血管事件呈階梯式上升

Osman Yousafzai

4002. Make It Standard: Lp(a) Integration For CV Risk Impact
北京時(shí)間：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
標(biāo)準(zhǔn)化：Lp(a) 整合對(duì)心血管風(fēng)險(xiǎn)的影響

Christie M. Ballantyne

北京時(shí)間：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
標(biāo)準(zhǔn)化：Lp(a)整合對(duì)心血管風(fēng)險(xiǎn)影響

Keith C. Ferdinand

北京時(shí)間：01:30
Make It Standard: Lp(a) Integration For CV Risk Impact
標(biāo)準(zhǔn)化：Lp(a)整合對(duì)心血管風(fēng)險(xiǎn)的影響

Fatima Rodriguez

402. Driving Impact at the Point of Care: Inside the ACC’s Solution Set Strategy
北京時(shí)間：00:55
Driving Urgency in LDL Screening
推動(dòng)低密度脂蛋白篩查的緊迫性

Timothy A. Dewhurst

03月30日

1446. Cardiovascular Disease Prevention 07
北京時(shí)間：00:00
ASSOCIATION BETWEEN LDL-C LOWERING AND REDUCED RISK OF CARDIOVASCULAR EVENTS: AN UPDATED SYSTEMATIC REVIEW AND META-REGRESSION
低密度脂蛋白膽固醇降低與心血管事件風(fēng)險(xiǎn)降低之間的關(guān)聯(lián)：一項(xiàng)更新的系統(tǒng)評(píng)價(jià)與元回歸分析

X. Zhang

1448. Ischemic Heart Diseases 07
北京時(shí)間：00:00
THE INCOMPLETE PREVENTION STORY: TRENDS IN LIPID PROFILES AND THERAPY PATTERNS BEFORE FIRST ACUTE MYOCARDIAL INFARCTION IN THE BMC2 REGISTRY
不完全的預(yù)防故事：BMC2登記研究中首次急性心肌梗死前血脂譜和治療模式的趨勢(shì)

M. Albdewi

1457. Complex Clinical Cases: Cardiovascular Disease Prevention 07
北京時(shí)間：00:00
STEPWISE COMBINATION THERAPY ACHIEVING SIGNIFICANT LDL-CHOLESTEROL REDUCTION IN SEVERE HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
逐步聯(lián)合治療在重度純合子家族性高膽固醇血癥中實(shí)現(xiàn)顯著的低密度脂蛋白膽固醇降低

Christine Kong

108. Cardiovascular Update For the Clinician I: A Symposium by Valentin Fuster
北京時(shí)間：01:51
Solving Statin Intolerance and Lp(a) Challenges: The Five Advances, Including RNA Agents With Infrequent SC Injections
解決他汀不耐受與脂蛋白(a)挑戰(zhàn)：五項(xiàng)進(jìn)展，包括間歇皮下注射的RNA藥物

Robert S. Rosenson

1116. Environment Influences on Prevention
北京時(shí)間：01:42
PM2.5 ACCELERATES ATHEROSCLEROSIS VIA ROS-INDUCED LDL OXIDATION AND ENDOTHELIAL PROGENITOR CELL DEPLETION: PROTECTIVE ROLE OF N-ACETYLCYSTEINE
PM2.5通過活性氧誘導(dǎo)的低密度脂蛋白氧化和內(nèi)皮祖細(xì)胞耗竭加速動(dòng)脈粥樣硬化：N-乙酰半胱氨酸的保護(hù)作用

Yuqi Cui

1469. Cardiovascular Disease Prevention 08
北京時(shí)間：01:30
TRENDS AND DEMOGRAPHIC DISPARITIES IN HYPERTENSION AND DYSLIPIDEMIA-RELATED MORTALITY IN OLDER AMERICAN ADULTS, 1999-2023
1999-2023年美國(guó)老年人高血壓和血脂異常相關(guān)死亡率的趨勢(shì)與人口統(tǒng)計(jì)學(xué)差異

R. Ochani

北京時(shí)間：01:30
FINDINGS FROM THE LISTEN-LDL-US (LIPID LOWERING THERAPY INSIGHTS PATIENT SURVEY ON TREATMENT EXPERIENCES AND NEEDS IN THE UNITED STATES) STUDY
來自LISTEN-LDL-US（美國(guó)降脂治療患者體驗(yàn)與需求洞察調(diào)查）研究的發(fā)現(xiàn)

Alejandro Victores

北京時(shí)間：01:30
COMPARATIVE EFFECTIVENESS OF CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY WITH OR WITHOUT AI-PLAQUE ANALYSIS AND STRESS TESTING ON LIPID LOWERING AFTER ONE YEAR: A PRIMARY ANALYSIS OF THE DECIDE (AI-DERIVED PLAQUE QUANTIFICATION: CTA AND AI-QCPA FOR DETERMINING EFFECTIVE CAD MANAGEMENT) REGISTRY
冠狀動(dòng)脈CT血管成像聯(lián)合或不聯(lián)合人工智能斑塊分析及負(fù)荷試驗(yàn)對(duì)一年后降脂效果的比較：DECIDE（人工智能衍生斑塊量化：用于確定有效冠狀動(dòng)脈疾病管理的CTA與AI-QCPA）登記研究的初步分析

Sarah Rinehart

1473. Multimodal Imaging 08
北京時(shí)間：01:30
PHYSIOLOGICAL CHANGES IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY USING AI-BASED MURRAY LAW-DERIVED QUANTITATIVE FLOW RATIO (μFR): INSIGHTS FROM THE YELLOW III STUDY
使用基于人工智能的默里定律衍生的定量血流比評(píng)估最大降脂治療前后非阻塞性冠狀動(dòng)脈病變的生理變化：來自YELLOW III研究的見解

P. Chenniganahosahalli

1480. Complex Clinical Cases: Cardiovascular Disease Prevention 08
北京時(shí)間：01:30
WHEN LIPIDS MISLEAD: A CARDIOLOGIST’S DILEMMA IN REFRACTORY HYPERTRIGLYCERIDEMIA
當(dāng)脂質(zhì)誤導(dǎo)：一位心臟病專家在難治性高甘油三酯血癥中的困境

Kristina Golovataya

305. When is Exercise the Risk? And When is It the Rx?
北京時(shí)間：03:20
Managing Hyperlipidemia in the Athlete
運(yùn)動(dòng)員的高脂血癥管理

James S. Guseh

1133. Social Factors Driving Cardiovascular Outcomes
北京時(shí)間：03:12
RELATIONSHIP BETWEEN GLYCEMIC CONTROL AND LIPID ABNORMALITIES IN FOOD INSECURE POPULATIONS
食物不安全人群中血糖控制與脂質(zhì)異常之間的關(guān)系

Tina Ting, MPH

1493. Cardiovascular Disease Prevention 09
北京時(shí)間：03:00
THE APOB-LDL-C CONTINUUM: INSIGHTS INTO TESTING TRENDS AND DISCORDANCE FROM A LARGE-SCALE LABORATORY STUDY
載脂蛋白B-低密度脂蛋白膽固醇連續(xù)譜：來自大規(guī)模實(shí)驗(yàn)室研究的檢測(cè)趨勢(shì)與不一致性的見解

Anjali Bhatla

北京時(shí)間：03:00
LDL CHOLESTEROL, NON-HDL CHOLESTEROL, APOLIPOPROTEIN B AND 30-YEAR RISK OF CARDIOVASCULAR DISEASE AMONG HEALTHY WOMEN
健康女性中低密度脂蛋白膽固醇、非高密度脂蛋白膽固醇、載脂蛋白B與30年心血管疾病風(fēng)險(xiǎn)的關(guān)系

Ask Nordestgaard

北京時(shí)間：03:00
PREVALENCE AND PRACTICE OF LP(A) TESTING IN HIGH RISK POPULATIONS AT THE UNIVERSITY OF KANSAS MEDICAL CENTER
堪薩斯大學(xué)醫(yī)學(xué)中心高風(fēng)險(xiǎn)人群中脂蛋白(a)檢測(cè)的普遍性與實(shí)踐

P. M. Moriarty

1495. Ischemic Heart Diseases 09
北京時(shí)間：03:00
CORONARY CT ANGIOGRAPHY FINDINGS DRIVE LIPID-LOWERING THERAPY INITIATION AND INTENSIFICATION IN CLINICAL PRACTICE
冠狀動(dòng)脈CT血管成像結(jié)果推動(dòng)臨床實(shí)踐中降脂治療的啟動(dòng)與強(qiáng)化

W. van de Vijver

1504. Complex Clinical Cases: Cardiovascular Disease Prevention 09
北京時(shí)間：03:00
HIDING IN PLAIN SIGHT: PARTIAL LIPODYSTROPHY WITH SEVERE DYSLIPIDEMIA, STATIN INTOLERANCE, AND PREMATURE CORONARY ARTERY DISEASE IN A TRIATHLETE
隱藏在明處：一名鐵人三項(xiàng)運(yùn)動(dòng)員的部分脂肪萎縮伴嚴(yán)重血脂異常、他汀不耐受及早發(fā)冠狀動(dòng)脈疾病

C. S. Agu

1506. Complex Clinical Cases: Ischemic Heart Diseases 09
北京時(shí)間：03:00
WHEN GAINS BECOME LOSSES: EXOGENOUS TESTOSTERONE AND CARNIVORE DIET LINKED TO SEVERE HYPERLIPIDEMIA AND PREMATURE CORONARY ARTERY DISEASE
當(dāng)獲益轉(zhuǎn)為損失：外源性睪酮與肉食飲食與嚴(yán)重高脂血癥及早發(fā)冠狀動(dòng)脈疾病相關(guān)

Mary Trejo Hernandez

1517. Cardiovascular Disease Prevention 10
北京時(shí)間：04:30
THE MI-TO-CVD RATIO IN LIPID-LOWERING TRIALS: EVOLVING PATTERNS AND IMPLICATIONS FOR FUTURE STUDY DESIGN
降脂試驗(yàn)中的心肌梗死與心血管疾病比值：演變模式及對(duì)未來研究設(shè)計(jì)的意義

R. Nair

1521. Multimodal Imaging 10
北京時(shí)間：04:30
AI-BASED ANGIOGRAPHY-DERIVED RADIAL WALL STRAIN IN NON-OBSTRUCTIVE CORONARY LESIONS BEFORE AND AFTER MAXIMAL LIPID-LOWERING THERAPY: INSIGHTS FROM THE YELLOW III STUDY
基于人工智能的血管造影衍生的非阻塞性冠狀動(dòng)脈病變?cè)谧畲蠼抵委熐昂髲较虮趹?yīng)變：來自YELLOW III研究的見解

P. Chenniganahosahalli

北京時(shí)間：04:30
IMPACT OF MAXIMAL LIPID LOWERING THERAPY ON THE PHYSIOLOGICAL DISEASE PATTERN USING AI BASED VIRTUAL μFR PULLBACK CURVE: INSIGHTS FROM THE YELLOW III STUDY
使用基于人工智能的虛擬μFR回撤曲線評(píng)估最大降脂治療對(duì)生理疾病模式的影響：來自YELLOW III研究的見解

P. Chenniganahosahalli

北京時(shí)間：04:30
INTRACORONARY IMAGING INSIGHTS INTO THE MORPHOLOGY OF CALCIFIED NODULES BEFORE AND AFTER MAXIMAL LIPID LOWERING THERAPY: A SUBSTUDY OF YELLOW III
最大降脂治療前后鈣化結(jié)節(jié)形態(tài)的冠狀動(dòng)脈內(nèi)影像學(xué)見解：YELLOW III研究的子研究

Pruthvi Chenniganahosahalli

1528. Complex Clinical Cases: Cardiovascular Disease Prevention 10
北京時(shí)間：04:30
A CASE OF REMARKABLE REDUCTION IN LDL FROM AKKERMANSIA PROBIOTIC
一例阿克曼氏菌益生菌顯著降低低密度脂蛋白膽固醇的病例

J. Helali

北京時(shí)間：04:30
THE PERFECT STORM: TACKLING THE TRIPLE THREAT OF LIPID DISORDERS, TYPE 1 DIABETES, AND AN INFLAMMATORY DISORDER IN A YOUNG WOMAN
完美風(fēng)暴：應(yīng)對(duì)年輕女性中脂質(zhì)紊亂、1型糖尿病和炎癥性疾病的三重威脅

J. Hicks

北京時(shí)間：04:30
BEATING THE ODDS: ADVANCED LIPID THERAPY ACHIEVES CONTROL IN CHYLOMICRONEMIA
戰(zhàn)勝逆境：先進(jìn)的脂質(zhì)治療實(shí)現(xiàn)乳糜微粒血癥的控制

Flavia Tejada

1538. Heart Failure and Cardiomyopathies 10
北京時(shí)間：04:30
TRENDS IN HEART FAILURE AND HYPERLIPIDEMIA-RELATED MORTALITY IN THE UNITED STATES: A RETROSPECTIVE ANALYSIS OF CDC WONDER FROM 1999 TO 2019
美國(guó)心力衰竭與高脂血癥相關(guān)死亡率的趨勢(shì)：1999年至2019年CDC WONDER數(shù)據(jù)庫(kù)的回顧性分析

A. Shabbir

1163. Advancing Lipid Management and Prevention in IHD
北京時(shí)間：22:30
ACHIEVED LDL-C IS ASSOCIATED WITH SAPHENOUS VEIN GRAFT PATENCY IN THE NEWTON-CABG CARDIOLINK-5 STUDY
在NEWTON-CABG CARDIOLINK-5研究中，達(dá)到的低密度脂蛋白膽固醇水平與大隱靜脈橋血管通暢性相關(guān)

Michael Szarek

北京時(shí)間：22:54
REAL-WORLD GAPS IN PRIMARY PREVENTION AND LIPID CONTROL AMONG PATIENTS PRESENTING WITH THEIR FIRST ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE NCDR CHEST PAIN-MI REGISTRY
首次急性心肌梗死患者在初級(jí)預(yù)防和血脂控制方面的真實(shí)世界差距：來自NCDR胸痛-心肌梗死登記研究的見解

Mohammed Essa

北京時(shí)間：23:06
RAPIDLY ESCALATED LIPID-LOWERING THERAPY EFFECTIVENESS IN PLAQUE STABILIZATION IN PATIENTS WITH ELEVATED LIPOPROTEIN(A)
快速升級(jí)的降脂治療在脂蛋白(a)升高患者中穩(wěn)定斑塊的有效性

Karlis Trusinskis

1164. Expanding Evidence for Nutrient Stimulated Hormone Therapies
北京時(shí)間：22:54
EFFECT OF ORFORGLIPRON, A NOVEL ORAL GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST, ON LIPID PANEL AND BLOOD PRESSURE: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
奧格列龍一種新型口服胰高血糖素樣肽-1受體激動(dòng)劑，對(duì)血脂譜和血壓的影響：隨機(jī)對(duì)照試驗(yàn)的薈萃分析

S. Kommu

1165. Lipid Control in Real-World Practice
北京時(shí)間：22:30
POST-MI LIPID MANAGEMENT: A PRACTICE PATTERN ANALYSIS OF THERAPY ESCALATION AND MONITORING GAPS IN CARE
心肌梗死后血脂管理：治療升級(jí)與護(hù)理監(jiān)測(cè)缺口的實(shí)踐模式分析

S. Khetrapal

北京時(shí)間：23:06
REAL-WORLD LIPID-LOWERING EFFICACY AND GOAL ATTAINMENT WITH ATORVASTATIN/EZETIMIBE FIXED-DOSE COMBINATION THERAPY
阿托伐他汀/依折麥布固定劑量聯(lián)合治療的真實(shí)世界降脂療效及目標(biāo)達(dá)成情況

Byung Gyu Kim

北京時(shí)間：23:18
LDL-C LOWERING AND ASSOCIATED RISK REDUCTION OF MYOCARDIAL INFARCTION AND STROKE-RELATED HOSPITALIZATIONS IN PATIENTS WITH ASCVD AND DIABETES
降低低密度脂蛋白膽固醇及其與動(dòng)脈粥樣硬化性心血管疾病和糖尿病患者心肌梗死及卒中相關(guān)住院風(fēng)險(xiǎn)降低的關(guān)聯(lián)

R. Jin

1541. Cardiovascular Disease Prevention 11
北京時(shí)間：22:30
PREVALENCE AND PATIENT CHARACTERISTICS OF PATIENTS WITH EXTREMELY HIGH ≥ 400 LDL-C LEVELS IN A LARGE INTEGRATED HEALTHCARE SYSTEM
大型綜合醫(yī)療系統(tǒng)中極高（≥ 400 mg/dL）低密度脂蛋白膽固醇水平患者的患病率及患者特征

J. S. Rana

1552. Complex Clinical Cases: Cardiovascular Disease Prevention 11
北京時(shí)間：22:30
WHEN LDL-C LIES - LIPOPROTEIN X MASQUERADING AS SEVERE HYPERCHOLESTEROLEMIA
當(dāng)?shù)兔芏戎鞍啄懝檀颊f謊時(shí)——脂蛋白X偽裝成嚴(yán)重高膽固醇血癥

R. Zhang

1562. Heart Failure and Cardiomyopathies 11
北京時(shí)間：22:30
EFFECT OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS ON HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION IN PATIENTS WITH OBESITY AND TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
GLP-1受體激動(dòng)劑對(duì)肥胖合并2型糖尿病患者輕度降低或保留射血分?jǐn)?shù)的心力衰竭的影響：一項(xiàng)系統(tǒng)評(píng)價(jià)與薈萃分析

B. Jeswani

276. Featured Clinical Research III
北京時(shí)間：01:35
Role Of Screening With Coronary Computed Tomography Angiography In Lipid Management In An Asymptomatic Chinese Population: A Community-based, Parallel-group, Open-label, Randomized Clinical Trial (RESPECT2)
冠狀動(dòng)脈CT血管造影篩查在無癥狀中國(guó)人群血脂管理中的作用：一項(xiàng)基于社區(qū)的、平行組、開放標(biāo)簽、隨機(jī)臨床試驗(yàn)（RESPECT2）

郭翔 中國(guó)人民解放軍東部戰(zhàn)區(qū)總醫(yī)院

1471. Ischemic Heart Diseases 08
北京時(shí)間：01:30
LIPID-LOWERING EFFICACY AND SAFETY OF OBICETRAPIB: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Obicetrapib的降脂療效與安全性：一項(xiàng)隨機(jī)對(duì)照試驗(yàn)的薈萃分析

Mariana Adieb

4014. Elevated Lp(a): Implications For Patient Risk Assessment
北京時(shí)間：03:45
Elevated Lp(a): Implications For Patient Risk Assessment
升高的脂蛋白(a)：對(duì)患者風(fēng)險(xiǎn)評(píng)估的意義

Payal Kohli

北京時(shí)間：03:45
Elevated Lp(a): Implications For Patient Risk Assessment
升高的脂蛋白(a)：對(duì)患者風(fēng)險(xiǎn)評(píng)估的意義

Sanjay Kaul

03月31日

1179. Improved Detection of ACS and CAD: Tests & Biomarkers
北京時(shí)間：00:24
CIRCULATING PLASMA MICRORNA PANEL FOR THE DETECTION OF LIPID-RICH CORONARY PLAQUES IN PATIENTS WITH EARLY-ONSET CORONARY ARTERY DISEASE.
用于檢測(cè)早發(fā)冠狀動(dòng)脈疾病患者富脂質(zhì)冠狀動(dòng)脈斑塊的血漿微小RNA組合

Evija Kana?niece

1180. Linking Lipid Metrics to CVD Risks
北京時(shí)間：00:00
CARDIOVASCULAR EVENTS IN PEOPLE WITH NORMAL LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS BUT DISCORDANTLY HIGH LEVELS OF SMALL/MEDIUM LDL PARTICLES
低密度脂蛋白膽固醇水平正常但小/中密度低密度脂蛋白顆粒水平不一致偏高的個(gè)體的心血管事件

Amand Schmidt

北京時(shí)間：00:24
BEYOND LDL CHOLESTEROL: TG/HDL-C RATIO AS A MARKER OF CARDIOVASCULAR RISK IN PEOPLE LIVING WITH HIV
超越低密度脂蛋白膽固醇：甘油三酯/高密度脂蛋白膽固醇比值作為HIV感染者的心血管風(fēng)險(xiǎn)標(biāo)志物

Kathleen Ebersol

北京時(shí)間：00:48
IMPACT OF LDL-C AND APOLIPOPROTEIN B LEVEL DISCORDANCE AND ASSOCIATED LIPOPROTEIN PARTICLE ALTERATIONS ON CARDIOVASCULAR OUTCOMES IN A LARGE PRIMARY PREVENTION POPULATION
低密度脂蛋白膽固醇與載脂蛋白B水平不一致及相關(guān)脂蛋白顆粒改變對(duì)大規(guī)模一級(jí)預(yù)防人群心血管結(jié)局的影響

Yuan Du 中國(guó)醫(yī)學(xué)科學(xué)院阜外醫(yī)院

1565. Cardiovascular Disease Prevention 12
北京時(shí)間：00:00
EFFICACY AND SAFETY OF ONGERICIMAB IN PATIENTS WITH DYSLIPIDEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
昂戈瑞西單抗在血脂異常患者中的療效與安全性：隨機(jī)對(duì)照試驗(yàn)的系統(tǒng)評(píng)價(jià)與薈萃分析

Basel Abdelazeem

北京時(shí)間：00:00
SAFETY AND EFFICACY OF SEQUENTIAL HIGH INTENSITY LIPID-LOWERING (SHILL) THERAPY FOR ATTAINMENT OF LDL-C GOAL AFTER ACUTE CORONARY SYNDROMES
序貫高強(qiáng)度降脂療法在急性冠狀動(dòng)脈綜合征后達(dá)到低密度脂蛋白膽固醇目標(biāo)的安全性與有效性

A. K. Pradhan

1576. Complex Clinical Cases: Cardiovascular Disease Prevention 12
北京時(shí)間：00:00
UNVEILING FAMILIAL SITOSTEROLEMIA: A SILENT CULPRIT BEHIND HYPERLIPIDEMIA IN AN ASYMPTOMATIC 28 YEAR-OLD MALE
揭示家族性谷固醇血癥：一名無癥狀28歲男性高脂血癥背后的隱匿元兇

K. Arora

361. What is the Risk of Lowering Cholesterol? Addressing Patient Concerns Regarding Lipid-Lowering Therapies
北京時(shí)間：01:18
Lipid-Lowering Therapies and HbA1c: Will Lowering My Cholesterol Give Me Diabetes?
降脂治療與糖化血紅蛋白：降低膽固醇會(huì)讓我得糖尿病嗎？

Erica Sarah Spatz

北京時(shí)間：01:28
Supplements and Cholesterol: What is the Role of OTCs in Lipid Management?
補(bǔ)充劑與膽固醇：非處方藥在血脂管理中的作用是什么？

Luke Laffin

1588. Cardiovascular Disease Prevention 13
北京時(shí)間：01:30
BEYOND STATINS IN ACUTE CORONARY SYNDROME—AN UPDATED META-ANALYSIS ON PCSK9 INHIBITORS AND THEIR IMPACT ON LIPID CONTROL, PLAQUE BURDEN, AND CLINICAL OUTCOMES
超越他汀，聚焦急性冠狀動(dòng)脈綜合征——關(guān)于PCSK9抑制劑及其對(duì)血脂控制、斑塊負(fù)荷和臨床結(jié)局影響的最新薈萃分析

A. Singla

北京時(shí)間：01:30
LDL CHOLESTEROL AND CARDIOVASCULAR RISK ACROSS OBESITY AND METABOLIC SYNDROME PHENOTYPES: INSIGHTS FROM THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
低密度脂蛋白膽固醇與心血管風(fēng)險(xiǎn)在肥胖及代謝綜合征不同表型中的差異：來自多民族動(dòng)脈粥樣硬化研究的見解

Beshoy Iskander

北京時(shí)間：01:30
EFFICACY OF INCLISIRAN FOR MORTALITY AND CARDIOVASCULAR EVENT PREVENTION ON PATIENTS WITH ELEVATED LDL CHOLESTEROL: AN UPDATED META-ANALYSIS
英克司蘭對(duì)低密度脂蛋白膽固醇升高患者死亡率和心血管事件預(yù)防的有效性：一項(xiàng)更新的薈萃分析

Arthur Petrucci

366. Investigative Horizons III
北京時(shí)間：03:21
Durability Of Enlicitide For Lipid Lowering: On-treatment Analysis Of Data From CORALreef Lipids And CORALreef HeFH Trials
Enlicitide降脂的持久性：來自CORALreef Lipids和CORALreef HeFH試驗(yàn)的治中數(shù)據(jù)分析

Ann Navar

POCKETIN 將挑選重點(diǎn)研究，就已發(fā)布結(jié)果邀請(qǐng)專家陸續(xù)解讀

POCKETIN接受投稿，我們將為撰稿作者提供該研究的過往詳細(xì)資料，資料包括：原文、演講幻燈、官方新聞、演講視頻等素材。并根據(jù)稿件質(zhì)量支付稿費(fèi)。

稿件將發(fā)表在POCKETIN、心關(guān)注微信公眾號(hào)上，并發(fā)表在國(guó)際期刊《翳望》（ISSN 2709-9105）上。同時(shí)，稿件將作為供稿提供給合作單位。

投稿請(qǐng)聯(lián)系：zhengsisi@medicaltelescope.cn 鄭思思

如發(fā)現(xiàn)文內(nèi)有誤請(qǐng)聯(lián)系我們

來源：ACC.26

POCKETIN

ACC.26

由蘇州工業(yè)園區(qū)東方華夏心血管健康研究院和醫(yī)望共同發(fā)起的POCKETIN項(xiàng)目將依托人工智能學(xué)術(shù)跟蹤系統(tǒng)，為全國(guó)廣大心血管醫(yī)師帶來及時(shí)全面的報(bào)道。

項(xiàng)目得到了醫(yī)師報(bào)、梅斯醫(yī)學(xué)、365醫(yī)學(xué)網(wǎng)、健康界、中華醫(yī)學(xué)信息導(dǎo)報(bào)、心關(guān)注、醫(yī)心、嚴(yán)道醫(yī)聲網(wǎng)等單位的大力支持。

▼更多精彩內(nèi)容，請(qǐng)長(zhǎng)按二維碼▼

1. 相關(guān)學(xué)術(shù)信息由醫(yī)望自主研發(fā)的人工智能學(xué)術(shù)跟蹤機(jī)器人提供。

2. 相關(guān)學(xué)術(shù)信息由醫(yī)望提供的醫(yī)學(xué)翻譯機(jī)器人完成翻譯后邀請(qǐng)臨床醫(yī)師進(jìn)行再次校對(duì)。
3. 如有內(nèi)容上的不準(zhǔn)確請(qǐng)微信聯(lián)系我們（zhengsisi@medicaltelescope.cn）

4. POCKETIN引入人工智能大語言模型，攜手專業(yè)編輯團(tuán)隊(duì)，開啟會(huì)議速遞全新體驗(yàn)。